Диссертация (1174231), страница 22
Текст из файла (страница 22)
Ghasemzadeh, J. Cammack, R. N. Adams // BrainRes. — 1991. — Vol. 547. — Р. 162–166.103. Glycogen synthase kinase-3 inhibitors: rescuers of cognitive impairments /M. K. King [et al.] // Pharmacol. Ther. — 2014. — Vol. 141(1). — Р. 1–12.104. Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicitycaused by the Huntington’s disease mutation / J. Carmichael, K.
L. Sugars, Y. P.Bao, D. C. Rubinsztein // J. Biol. Chem. — 2002. — Vol. 277(37). — Р. 33791–33798.105. Goodwin, F. K. Manic-Depressive Illness: Bipolar and Recurrent Unipolar Disorders / F. K. Goodwin, K. R. Jamison. — 2th ed. — New York : Oxford UniversityPress, 2007.106. Gordon, P. H. Amyotrophic lateral sclerosis: pathophysiology, diagnosis andmanagement / P. H. Gordon // CNS Drugs. — 2011. — Vol.
25(1). — Р. 1–15.145107. Gould, T. D. In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3 / T. D. Gould, G. Chen, H. K. Manji // Neuropsychopharmacology. — 2004. — Vol. 29(1). — Р. 32–38.108. Greasley, P. J. Bovine inositol monophosphatase. Studies on the binding interactions with magnesium, lithium and phosphate ions / P.
J. Greasley, M. G. Gore //FEBS Lett. — 1993. — Vol. 331(1–2). — Р. 114–118.109. Grimes, C. A. The multifaceted roles of glycogen synthase kinase 3β in cellularsignaling / C. A. Grimes, R. S. Jope // Prog Neurobiol. — 2001. — Vol. 65(4). —Р. 391–426.110. GSK-3alpha regulates production of Alzheimer’s disease amyloid-β peptides /C. J. Phiel, C. A. Wilson, V. M.
Lee, P. S. Klein // Nature. — 2003. —Vol. 423(6938). — Р. 435–439.111. Hallcher, L. M. The effects of lithium ion and other agents on the activity of myoinositol-1-phosphatase from bovine brain / L. M. Hallcher, W. R. Sherman //J. Biol. Chem. — 1980. — Vol. 255. — Р. 10896–10901.112. Han, J.-Y. Primary prevention of Alzheimer s disease: Is it an attainable goal /J.-Y.
Han, S.-H. Han // J. Korean Med. Sci. — 2014. — Vol. 29. — P. 886–892.113. Hellweg, R. Baumgartner A. Subchronic treatment with lithium increases nervegrowth factor content in distinct brain regions of adult rats / R. Hellweg,U. E. Lang, M. Nagel // Mol. Psychiatry. — 2002. — Vol. 7(6). — Р. 604–608.114. Hickey, M. A.
Apoptosis in Huntington’s disease / M. A. Hickey, M. F.Chesselet // J. Prog. Neuropsychopharmacol Biol. Psychiatry. — 2003. —Vol. 27(2). — Р. 255–265.115. High fruit and vegetable intake is positively correlated with antioxidant status andcognitive performance in healthy subjects / M. C. Polidori [et al.] // J. of Alzheimer’s disease. — 2009.
— Vol. 17. — Р. 921–927.116. Hooper, C. The GSK3 hypothesis of Alzheimer’s disease / C. Hooper, R. Killick,S. Lovestone // J. Neurochem. — 2008. — Vol. 104(6). — Р. 1433–1439.146117. Hypoxia activates glycogen synthase kinase-3 in mouse brain in vivo: protectionby mood stabilizers and imipramine / M. S. Roh [et al.] // J. Biol. Psychiatry. —2005. — Vol.
57(3). — Р. 278–286.118. In vitro effects of lithium chloride on TNF alpha and IL-6 production by monocytes from breast cancer patients / A. Arena [et al.] // J. Chemother. — 1997. —Vol. 9(3). — Р. 219–226.119. Inactivation of glycogen synthase kinase 3 promotes axonal growth and recoveryin the CNS / J.
Dill, H. Wang, F. Zhou, S. Li // J. Neurosci. — 2008. —Vol. 28. — Р. 8914–8928.120. Increased bcl-2 protein levels in rat primary astrocyte culture following chroniclithium treatment / M. Keshavarz [et al.] // Iran. J. Med. Sci. — 2013. —Vol. 38. — Р. 255–262.121. Increased BMP6 levels in the brains of Alzheimer’s disease patients and APPtransgenic mice are accompanied by impaired neurogenesis / L. Crews [et al.] //J. Neurosci. — 2010. — Vol.
30(37). — Р. 12252–12262.122. Inestrosa, N. C. Wnt signaling in the nervous system and in Alzheimer’s disease /N. C. Inestrosa, L. Varela-Nallar // J. Mol. Cell. Biol. — 2014. — Vol. 6(1). —Р. 64–74.123. Inhibition of glycogen synthase kinase-3 by lithium correlates with reducedtauopathy and degeneration in vivo / W. Noble [et al.] // Proc. Natl. Acad. SciUSA. — 2005. — Vol. 102(19). — Р. 6990–6995.124. Inhibition of GSK-3 reduces infarct volume and improves neurobehavioral functions / S. H.
Koh [et al.] // Biochem Biophys Res Commun. — 2008. —Vol. 371(4). — Р. 894–899.125. Inositol-deficient food augments a behavioral effect of long-term lithium treatment mediated by inositol monophosphatase inhibition: an animal model with relevance for bipolar disorder / L. Shtein, G. Agam, R. H. Belmaker, Y. Bersudsky //J. Clin. Psychopharmacol. — 2015.
— Apr, 35(2). — Р. 175–177.147126. Insulin resistance is associated with high sodium–lithium countertransport in essential hypertension / A. Doria [et al.] // Am. J. Physiol. — 1991. — Vol. 261(6 Pt 1). — Р. 684–691.127. Insulin-like growth factor 1 (IGF-1) expression is up-regulated in lymphoblastoidcell lines of lithium responsive bipolar disorder patients / A.
Squassina [et al.] //Pharmacol Res. — 2013. — Vol. 73. — Р. 1–7.128. Intakes of vitamin C and carotenoids and risk of amyotrophic lateral sclerosis:Pooled results from 5 cohort studies / K. C. Fitzgerald [et al.] // Ann Neurol. —2013. — Vol. 73. — Р. 236–245.129. Is lithium a neuroprotective agent? / T. M. Vo, P. Perry, M.
Ellerby, K. Bohnert //Ann. Clin. Psychiatry. — 2015. — Vol. 27(1). — Р. 49–54.130. Ishikawa, T. Molecular cloning and functional expression of rat liver glutathione–dependent dehydroascorbate reductase / T. Ishikawa, A. F. Casini, M. Nishikimi /J. Biol. Chem. — 1998. — Vol. 273. — Р. 28708–28712.131. Joffe, R. T. Hematological effects of lithium potentiation of carbamazepine in patients with affective illness / R. T.
Joffe // Int. Clin. Psychopharmacol. —1988. — Vol. 3(1). — Р. 53–57.132. Jope, R. S. Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes / R. S. Jope // Trends. Biochem. Sci. — 2003. — Vol. 24(9). — Р. 441–443.133. Kaidanovich, O. The role of glycogen synthase kinase-3 in insulin resistance andtype 2 diabetes / O. Kaidanovich, H. Eldar-Finkelman // Expert Opin. Ther. Targets. — 2002. — Vol.
6(5). — Р. 555–561.134. Kalinichev, M. Evidence for antimanic efficacy of glycogen synthase kinase-3(GSK3) inhibitors in a strain-specific model of acute mania / M. Kalinichev,L. A. Dawson // Int. J. Neuropsychopharmacol. — 2011. — Vol. 14(8). — Р.1051–1067.135. Kessing, L. V. Does lithium protect against dementia? / L. V. Kessing, J.
L. Forman, P. K. Andersen // Bipolar Disord. — 2010. — Vol. 12(1). — Р. 87–94.148136. Lenalidomide (revlimid) administration at symptom onset is neuroprotective in amouse model of amyotrophic lateral sclerosis / A. Neymotin [et al.] / Exp.Neurol. — 2009. — Vol. 220. — Р. 191–197.137.
Lerer, B. Does lithium stabilize muscarinic receptors? / B. Lerer, M. Stanley //Biol. Psychiatry. — 1985. — Vol. 20(11). — Р. 1247–1250.138. Levine, M. Analysis of ascorbic acid and dehydro-ascorbic acid in biologicalsamples / M. Levine, Y. Wang, S. C.
Rumsey // Methods Enzymol. — 1999. —Vol. 299. — Р. 65–76.139. Li, X. Glycogen synthase kinase-3β, mood stabilizers, and neuroprotection / X. Li,N. G. Bijur, R. S. Jope // Bipolar Disorder. — 2002. — Vol. 4, № 2. — Р. 137–144.140. LiCl attenuates thapsigargin-induced tau hyper phosphorylation by inhibitingGSK-3β in vivo and in vitro / Z. Q. Fu [et al.] // J. Alzheimer’s Dis. — 2010. —Vol.
21(4). — Р. 1107–1117.141. Lithium — pharmacological and toxicological aspects: the current state of the art /B. Medić [et al.] // Curr. Med. Chem. — 2018. — Sep. 4.142. Lithium and hematology: established and proposed uses / D. Focosi [et al.] //J. Leukoc Biol. — 2009. — Vol. 85(1). — Р. 20–28.143. Lithium and oxidative stress lessons from the MPTP model of Parkinson’s disease / Z. Arraf, T. Amit, M. B. Youdim, R. Farah // Neurosci Lett. — 2012. —Vol. 516(1). — Р.
57–61.144. Lithium chloride disrupts consolidation of morphine–induced conditioned placepreference in male mice: the nitric oxide/cyclic GMP signaling pathway /A. Kiyani [et al.] // Behav. Brain Res. — 2011. — Vol. 219(2). — Р. 240–247.145. Lithium chloride promotes host resistance against Pseudomonas aeruginosa keratitis / K. Chen [et al.] // Mol.
Vis. — 2013. — Vol. 19. — Р. 1502–1514.146. Lithium chloride reinforces the regeneration-promoting effect of chondroitinaseABC on rubrospinal neurons after spinal cord injury / L. W. Yick, K. F. So,P. T. Cheung, W. T. Wu // J.
Neurotrauma. — 2004. — Vol. 21. — Р. 932–943.149147. Lithium citrate as treatment of Canavan disease / M. D. Solsona, L. L. Fernández,E. M. Boquet, J. L. Andrés // Clin. Neuropharmacol. — 2012. — Vol. 35(3). —Р. 150–151.148. Lithium citrate reduces excessive intra-cerebral N-acetyl aspartate in Canavandisease / M. Assadi [et al.] // Eur. J. Paediatr Neurol. — 2010. — Vol. 14(4). —Р. 354–359.149.
Lithium decreases secretion of Aβ1-42 and C-truncated species Aβ1-37/38/39/40in chicken telencephalic cultures but specifically increases intracellular Aβ1-38 /H. Esselmann [et al.] // Neurodegener Dis. — 2004. — Vol. 1(4–5) — Р. 236–241.150. Lithium delays progression of amyotrophic lateral sclerosis / F. Fornai [et al.] //Proc Natl Acad. Sci. USA. — 2008. — Vol. 105(6). — Р. 2052–2057.151. Lithium enhances the neuronal differentiation of neural progenitor cells in vitroand after transplantation into the avulsed ventral horn of adult rats through the secretion of brain-derived neurotrophic factor / H.
Su [et al.] // J. Neurochem. —2009. — Vol. 108. — Р. 1385–1398.152. Lithium increases nerve growth factor levels in the rat hippocampus in an animalmodel of mania / B. N. Frey [et al.] // Behav. Pharmacol. — 2006. —Vol. 17(4). — Р. 311–318.153. Lithium increases plasma brain-derived neurotrophic factor in acute bipolar mania: a preliminary 4-week study / R. T. De Sousa [et al.] // Neurosci Lett. —2011. — Vol.
494(1). — Р. 54–56.154. Lithium increases platelet serine-9 phosphorylated GSK-3β levels in drug-free bipolar disorder during depressive episodes / R. T. De Sousa [et al.] // J. Psychiatr.Res. — 2015. — Vol. 62. — Р. 78–83.155. Lithium induces brain-derived neurotrophic factor and activates TrkB in rodentcortical neurons: an essential step for neuroprotection against glutamateexcitotoxicity / R. Hashimoto [et al.] // Neuropharmacology. — 2002. —Vol. 43(7). — Р.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
